Phase 3 Readout~month

Phase 3 Topline: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early Sta

Drug
early
Indication
Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Lung Non-Small Cell Carcinoma

Other upcoming events for ADMA

Patent ExpiryPatent/Exclusivity Expiry: GILOTRIF
Patent ExpiryPatent/Exclusivity Expiry: ALIQOPA
Patent ExpiryPatent/Exclusivity Expiry: TAFINLAR

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early Sta — ADMA Phase 3 Readout | BioSniper